Lumosa Therapeutics (TWO:6535)

Executive Summary

Lumosa Therapeutics is a Taiwan-based clinical-stage biopharmaceutical company developing novel small-molecule and biologic therapies for neurological, oncological, and cardiovascular indications. The company's lead asset, LT3001, is a recombinant tissue plasminogen activator (rt-PA) variant designed for acute ischemic stroke with an extended therapeutic window and reduced bleeding risk. LT3001 is currently in Phase 2 trials, with topline data expected in late 2026. Another key candidate, LT1001 (nalbuphine sebacate), is a long-acting analgesic for postoperative pain, which has completed Phase 2 and is being prepared for Phase 3. Lumosa also leverages a proprietary T-cell enhancement platform for oncology applications. With a public listing on the Taiwan Stock Exchange (TWO:6535) and a focused pipeline, the company aims to address significant unmet medical needs. However, the stock remains volatile due to binary readout risks.

Upcoming Catalysts (preview)

• Q4 2026LT3001 Phase 2 topline data for acute ischemic stroke55% success
• Q2 2026LT1001 Phase 3 trial initiation for postoperative pain70% success
• Q3 2026T-cell enhancement platform preclinical data update60% success